Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label UM171-expanded single cord blood transplantation for high-risk acute leukemia or myelodysplasia
NL-OMON53840Phase 2Recruiting
- Sponsor
- ExCellThera
- Start
- Jan 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dorocubicel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more, sponsored by ExCellThera. Primary endpoints: Safety and feasibility of infusing a single ECT-001-expanded cord blood, Relapse-free survival and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
dorocubicel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON53840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53840.